Final answer:
The dosage of Ixekizumab for pediatric patients with plaque psoriasis varies based on the child's body mass, and careful consideration of liver or kidney function is essential to minimize side effects and prevent toxicity.
Step-by-step explanation:
The dosage of Ixekizumab (Taltz) for pediatric patients with plaque psoriasis must be carefully determined to balance therapeutic benefits while minimizing potential side effects. In children, this dosage is typically based on the patient's body mass, meaning that the dosage will vary according to the weight of the child. In contrast, for adults and children 12 years of age and older, a single standard dose is usually prescribed.
It is essential to consider a patient's history of liver or kidney dysfunction as it can affect drug metabolism and clearance, potentially leading to increased drug levels and a higher probability of toxicity. Therefore, individual patient characteristics and medical history play a crucial role in determining the safest and most effective dosage regimen for pediatric patients taking Ixekizumab.